| INTRODUC TI ON
Telomerase, consisting of TERT and telomerase RNA component, adds telomeric repeat DNA sequences (TTAGGG) at the end of eukaryotic linear chromosomes to protect DNA from end-to-end fusion, rearrangement, and translocation. 1, 2 Cell mitosis results in progressive shortening of telomeres and leads to cell senescence; therefore, immortal cells constitutively activate telomerase to maintain telomere length and escape from telomere-induced replicative senescence. [3] [4] [5] [6] A recent study clarified that increased expression of TERT also promotes immortalization by bypassing oncogene-induced senescence. 7 This is consistent with the observation that TERT gene expression is activated in more than 90% of cancers, irrespective of tumor type.
8
Hepatocellular carcinoma is the third leading cause of cancerrelated death. 9 Hepatocellular carcinoma and cirrhotic premalignant lesions frequently show increased expression of TERT, whereas mature and senescent hepatocytes have low TERT expression. 6, [10] [11] [12] [13] The difference in TERT expression between these 2 tissue types suggests that telomerase reactivation plays an important role in hepatocarcinogenesis.
14 Indeed, TERT promoter mutation resulting in activation of TERT expression is the most frequent genetic alteration in HCC and is seen in 61% of HCC tissues and in 19% of premalignant nodules. 11, 15, 16 These results indicate that TERT is a possible target for HCC therapy. 17 However, a direct telomerase inhibitor was frequently associated with adverse events and failed to improve the prognosis of non-smallcell lung cancer patients in a phase II study. 18 TERT expression is the primary determinant regulating the telomerase activity in cancer cells 12 and a number of studies examining TERT expression in cancer have been published, most of which have investigated promoter mutations and chromosomal rearrangements.
19
Suppression of TERT transcription is a reasonable approach to target telomerase; therefore, it is important to identify the genes that regulate TERT transcription.
In the present study, we undertook an unbiased screen of TERT promoter activators using a genome-wide shRNA library. This screening system succeeded in identifying 2 previously unrecognized activators of TERT transcription. These activators are expected to be novel therapeutic targets for HCC.
| MATERIAL S AND ME THODS

| Plasmids and lentiviruses
Short hairpin RNA expression vectors for C15orf55, C7orf43, F2, SLC22A16, CLEC4C, and LZTR1, and expression vectors for
C15orf55 and C7orf43 and their negative controls (sh-empty and pcDNA6-empty) were used in this study. Firefly luciferase reporter vectors driven by multiple lengths of the TERT promoter are described in Figure S1 . The lentiviruses were generated based on former shRNA vectors using Second Generation Packaging Mix (Applied Biological Materials, Richmond, Canada) and 293T cells. All constructs were verified by direct DNA sequencing.
| Cell lines and cell culture
HepG2 cells were maintained in DMEM supplemented with 10%
FBS. HepG2 sublines were established by transfection of the cells with pcDNA6-Empty (OE-Empty), pcDNA6-C15orf55 (OEC15orf55), and pcDNA6-C7orf43 (OE-C7orf43).
| Short hairpin RNA library screening
A lentivirus-based shRNA library (hGW shRNA Library Module 2;
Cellecta inc., Mountain View, CA) was transduced into HepG2 cells, which were doubly transfected with both TERT promoter-driven GFP and an exogenous TERT expression vector to maintain steady growth of cells. Selection with puromycin and cell-sorting was carried out to detect cells that suppressed TERT promoter activity.
| Patient samples
Liver tumor tissue and adjacent nontumor liver tissue from 65 HCC patients were acquired following surgery for HCC between 2007
and 2011 at the Tottori University Hospital (Yonago, Japan). The study was approved by the ethical committee of Tottori University (1610A118). The data of 377 HCC patients in TCGA dataset (https:// cancergenome.nih.gov/) were also examined.
| Statistical analysis
All statistical analyses were carried out using R software (version 3.1.3; www.r-project.org/). P < .05 was considered to indicate significant difference. Additional information is provided in Appendix S1.
| RE SULTS
| Identification of C15orf55 and C7orf43 as activators of the TERT promoter
To identify genes that activate TERT transcription, we carried out an shRNA screen of HepG2 human HCC cells that were genetically modified to express exogenous TERT to compensate for the decreased expression of endogenous TERT by shRNA ( Figure 1A ).
One hundred clones with low TERT promoter activity were obtained after shRNA-transduction of HepG2 cells. From these clones, 6
genes were identified as potential activators of TERT transcription (Tables S1 and S2 
| Effect of C15orf55 and C7orf43 on HepG2 cell proliferation
As TERT promotes cell proliferation through several pathways, [20] [21] [22] we attempted to investigate the effect of C15orf55 and C7orf43 on cell proliferation. Both OE-C15orf55 and OE-C7orf43 clones grew faster in a plane culture, and formed larger colonies in a methylcellulose medium than OE-Empty clone did ( Figures 3A and S4 ). 
| Involvement of SP1 in TERT promoter activation by C15orf55
The region of the TERT promoter responsible for C15orf55-induced activation (−58 to +36) contains 2 GC motifs, a region to which SP1 binds to induce TERT expression. 23 To investigate whether C15orf55
regulates TERT transcription through SP1 on the GC motifs, 2 reporter vectors carrying 1 or the other of the GC motifs were constructed ( Figure S1B ). C15orf55 was shown to activate TERT expression through both GC motifs ( Figure 5A ). Furthermore, mithramycin, a competitive inhibitor of SP1 for binding to the GC motif, 24 prevented
C15orf55-mediated activation of the TERT promoter ( Figure S5A ).
The siRNA-mediated SP1 knockdown canceled C15orf55-induced activation of the TERT promoter ( Figure S5B ,C). Consistent with this observation, significantly more SP1 was recruited to the GC motifs in the TERT promoter in OE-C15orf55 cells than in OE-Empty cells ( Figure 5B ). These data indicate that C15orf55 activates TERT expression through SP1 on the promoter ( Figure 5F ).
| Involvement of YAP1 in TERT promoter activation by C7orf43
Although our luciferase assay indicated that the region from −169
to −59 bp of the TERT promoter is responsible for C7orf43-induced activation of the promoter, only a few transcription factors that F I G U R E 2 HepG2 cells with stable C15orf55 (OE-C15orf55) or C7orf43 (OE-C7orf43) expression have activated TERT and telomerase expression. A, Western blot analysis for OE-C15orf55 and OE-C7orf43. B, Quantitative telomerase repeat amplification protocol assay. Results are expressed as the mean ± SD, n = 3. *P < .05
Overexpression of C15orf55 or C7orf43 promotes cell proliferation, whereas knockdown (KD) of C15orf55 or C7orf43 inhibits colony formation ability. A, Cell proliferation plots for cells stably expressing each gene. n = 4. B, Colony formation assay using shRNA lentivirus. Number of colonies 20 days after induction of shRNAs using lentivirus; n = 3. C, Typical colonies in the colony formation assay. Scale bar = 10 mm. Results are expressed as the mean ± SD. *P < .05
bind to this region have been reported, including GABPA, E2F1, HIF1, and paired box family 8. 19 To determine the site responsible for C7orf43-induced activation, this region was divided into 6 sequences (fragments #1-#6, Figure S1C ). Luciferase reporter assays using these reporter vectors revealed that C7orf43 activated fragment #3 containing unknown transcription factor binding sites, and fragment #6 containing the C228T mutation-dependent GABPA-binding site ( Figure 5C ). 25 The JASPAR program indicated that transcription factor EGR1 might bind to fragment #3 (JASPAR 2018 database, http://jaspar.genereg.net/). Yes-associated protein 1 is commonly associated with EGR1 and GABPA. 26, 27 Moreover, C7orf43 interacts with AMOTL2, which is a suppressor of YAP1
and a target gene of the Hippo pathway. 28, 29 To evaluate the effect of C7orf43 overexpression on YAP1 activity, the expression and nuclear localization of YAP1 were examined in OE-C7orf43 cells.
As expected, the protein levels of YAP1 and AMTOL2 were upregulated, whereas C7orf43 did not affect YAP1 phosphorylation, which represses YAP1 activity through the cytosolic retention of YAP1 ( Figure 5D ). 30 Nuclear localization of YAP1 was also significantly increased in OE-C7orf43, compared to OE-Empty cells, as indicated by immunofluorescent staining and immunoblotting of nuclear extracts (Figures 5E and S6 ). In addition, it was shown that C7orf43-induced activation of TERT promoter was canceled by siRNA-mediated knockdown of YAP1 ( Figure S7 ). Our data indicate that C7orf43 activation of YAP1 is dominant over AMOTL2-mediated suppression of YAP1. Taken together, these data indicate that C7orf43 activates the TERT promoter via YAP1 ( Figure 5F ). Child-Pugh score (P = .046; Figure 6C ). Although it did not reach statistical significance, C7orf43 expression also showed a tendency to be associated with liver cirrhosis (P = .197; Figure 6D ). The expression levels of C15orf55 and C7orf43 were significantly correlated with TERT expression levels both in nontumor and tumor tissues of HCC patients ( Figure 7A-D) . Although the detection rate of TERT mRNA in tumor and nontumor tissue appears to be low, TERT mRNA levels were also reported to be very low or undetectable in previous studies. 31, 32 Given the existence of the correlation in nontumor tissues in which the frequency of TERT promoter mutation is quite low, 
| D ISCUSS I ON
Expression of TERT is critical for the reactivation of telomerase, which plays an important role in the development and proliferation of cancer cells through telomere protection and avoidance of senescence. However, the mechanism by which hepatocytes acquire telomerase reactivation at the initiation of cancer remains largely unclear. Interestingly, a small subpopulation of hepatocytes with elevated Tert expression and telomerase activity exists in the liver of healthy mice to drive the regeneration and renewal of the liver, 33 indicating that telomerase reactivation could be an intrinsic function in progenitor hepatocytes rather than resulting from genomic change, such as mutation or methylation.
In the present study, we used a lentivirus-based shRNA library.
The pooled shRNA library is a valuable tool for gene screening. It has identified NQQ1 as a potential drug target for host-directed tuberculosis therapy, ATP1A1 as a gene that regulates aurilide B cytotoxicity, and the deubiquitinating enzyme, USP5, which modulates cell cycle regulators. [34] [35] [36] The shRNA screening system has also identified HIF1α as a TERT regulator using mouse ES cells. 37 In this study in a HCC cell line, we identified two genes, C15orf55, also known as NUTM1, is a testis-specific protein with totally unknown function. 38 However, it is not surprising that C15orf55 promotes carcinogenesis and proliferation of cancer cells because the fusion of C15orf55 with BRD4, which encodes a bromodomain-containing protein, is commonly found in a rare carcinoma arising in midline organs (OMIM: 608963). 39, 40 Although the domain corresponding to C15orf55 of the C15orf55-BRD4 fusion protein activated p300 histone acetyltransferase and chromatin remodeling, 40 no attenuation of C15orf55-induced promoter activation was found in a reporter assay using C646, a specific inhibitor of CBP/P300 (data not shown). These data suggest that C15orf55
activates the TERT promoter in a CBP/P300-independent manner.
TA Instead, we found that SP1 is a critical transcription factor for C15orf55-induced activation of the TERT promoter. SP1 plays an important role in the transcriptional regulation of TERT. 22 Although a number proteins interact with SP1, little is known about a mechanism that regulates SP1 to activate the transcription of TERT. In this study, C15orf55 was identified as a novel upstream factor of SP1.
C7orf43, the other regulator of TERT transcription identified in our study, is also an uncharacterized protein. We found that C7orf43 activates YAP1, the main downstream effector of the Hippo signaling pathway, whose activation negatively regulates YAP1. YAP1 is suggested to be an oncogene in humans because its upregulation and nuclear localization have been observed in multiple types of human cancer. [41] [42] [43] [44] [45] [46] [47] Moreover, knockdown or deletion of Hippo pathway components, such as Mst1/2, in liver lead to the activation of YAP1 and the development of HCC. 48 Before this study, interaction between YAP1 and C7orf43 was unknown; however, an interactome analysis showed that C7orf43 interacts with AMOTL2. 49 The latter suppresses YAP1 by tethering it in the cytoplasm. 28 Note that AMOTL2 is also the target gene of YAP1 as a negative feedback regulator of the Hippo pathway. 27, 28 As shown in Figure 5C , C7orf43 induced AMOTL2 expression, but YAP1 was still activated, suggesting that the negative feedback regulation might be abrogated by and to immortalize the cells. 50 Our data suggest that C15orf55 and C7orf43 might be critical factors for the reactivation of telomerase in HCC, in addition to the promoter mutation.
Consistent with our in vitro observations, C15orf55 and C7orf43 had a negative impact on patients' prognosis. Our findings indicate that upregulation of these genes induces tumor progression through telomerase reactivation, which strongly associates with poor prognosis of HCC patients. 51, 52 Based on these results, further studies to reveal the precise mechanisms in which these genes act could lead to the development of a novel telomerase inhibitor. Interestingly, it is also possible that C15orf55 and C7orf43 themselves promote cell proliferation in a TERT-independent manner, because C15orf55
and C7orf43 activate SP1 and YAP1, respectively, both of which have various functions for cell proliferation other than TERT. 46, 48, 53 Therefore, it is worth investigating whether C15orf55 or C7orf43 has tumorigenic potential independent of TERT. The mechanism of how these genes activate SP1 and YAP1 could provide useful information for a novel HCC therapy.
A recent study by Lin et al showed that a small population of hepatocytes expressing high levels of TERT (TERT high ) in healthy liver is involved in hepatocyte renewal. 33 Their transcriptome analysis revealed that several genes related to SP1 and YAP1 are significantly 
ACK N OWLED G M ENTS
We thank Jeremy Allen, PhD, from Edanz Group for editing a draft of this manuscript. This work was supported by the Japan Society for the Promotion of Science KAKENHI (grant no. 17K16556).
CO N FLI C T O F I NTE R E S T
We declare the following conflict of interest: GS has more than 5% of the total shares of KanonCure Inc. The other authors have no competing interests.
O RCI D
Masataka
Amisaki https://orcid.org/0000-0003-4153-4036
Hiroyuki Tsuchiya https://orcid.org/0000-0002-2144-8272
R E FE R E N C E S
